Table 1.
Characteristics of SS-associated lymphoma patients, first-line treatments and CR rates, according to NHL subtypes.
Table 2.
Differentiation of laboratory findings, SS systemic manifestations and SS activity, according to total ESSDAI score, 6-months after NHL treatment.
Table 3.
Summary of 22 SS-associated NHL-patients that experienced an event during follow-up.
Fig 1.
Survival of SS-associated lymphoma patients.
A. Kaplan-Meier for OS and EFS for the entire cohort of SS-associated lymphoma patients. 5-year (%) OS for the entire lymphoma cohort: 90.91% (95%CI: 82.14–95.80%) and 5-year (%) EFS for the entire cohort: 77.92% (95% CI: 67.37–85.82%). B. Kaplan-Meier for OS of SS-associated lymphoma patients, according to lymphoma subtypes (log-rank p = 0.188). C. Kaplan-Meier for EFS of SS-associated lymphoma patients, according to lymphoma subtypes (log-rank test, P = 0.015).
Table 4.
Effects of prognostic parameters at the point of lymphoma diagnosis in SS-associated NHL patients’ outcomes.
Fig 2.
High SS disease activity, adverse IPI score and bone marrow involvement impair survival of lymphoma patients.
A. and B. Kaplan-Meier for EFS and OS of SS-associated lymphoma patients, according to high or low total ESSDAI score groups (High total ESSDAI>10 and Low total ESSDAI≤10). High vs. Low total ESSDAI group for EFS: log-rank p = 0.001 and for OS: log-rank p = 0.011. C. and D. Kaplan-Meier for EFS and OS of the SS-associated NHL patients, according to IPI score groups: low/low-intermediate IPI group = 0–2 factors and high-intermediate/high IPI group = 3–4 factors. Log-rank test of low/low-intermediate vs. high-intermediate/high risk group curves for EFS: p< 0.001 and for OS: p<0.001. E. and F. Kaplan-Meier for EFS and OS of the SS-associated NHL patients, according to bone marrow involvement (log-rank test for EFS: p = 0.001 and for OS: p = 0.152).